Inactive Instrument

Antares Pharma, Inc.

Equities

ATRS

US0366421065

Medical Equipment, Supplies & Distribution

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Antares Pharma, Inc. Announces Management Changes CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from NASDAQ Composite Index CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Pharmaceuticals Select Industry Index CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Global BMI Index CI
Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P TMI Index CI
Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc.. CI
Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition MT
Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares MT
Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy MT
HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60 MT
Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6 MT
Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy MT
Sector Update: Health Care Stocks Putting Up Modest Gains This Afternoon MT
Health Care Up Amid Deal Activity -- Health Care Roundup DJ
Sector Update: Health Care Stocks Edging Higher Wednesday Afternoon MT
Top Midday Gainers MT
Truist Securities Downgrades Antares Pharma to Hold From Buy, Adjusts PT to $5.60 From $7.00 MT
Halozyme to Acquire Antares Pharma for $960 Million; Antares Shares Surge MT
Wall Street Set for Muted Open as Traders Digest BlackRock, JPMorgan Earnings; Producer Prices Rise More Than Expected MT
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday MT
Top Premarket Gainers MT
North American Morning Briefing: Stock Futures Tick Up Ahead of Earnings DJ
Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Antares Pharma, Inc. for $970 million. CI
Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy MT
Chart Antares Pharma, Inc.
More charts
Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.
More about the company
  1. Stock
  2. Equities
  3. Stock Antares Pharma, Inc. - Nasdaq
  4. News Antares Pharma, Inc.
  5. Antares Pharma : Boosts Full-Year 2020 Revenue Guidance